DE60309888D1 - Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen - Google Patents

Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen

Info

Publication number
DE60309888D1
DE60309888D1 DE60309888T DE60309888T DE60309888D1 DE 60309888 D1 DE60309888 D1 DE 60309888D1 DE 60309888 T DE60309888 T DE 60309888T DE 60309888 T DE60309888 T DE 60309888T DE 60309888 D1 DE60309888 D1 DE 60309888D1
Authority
DE
Germany
Prior art keywords
apolipoprotein
trypanosoma
treatment
diseases
derivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60309888T
Other languages
English (en)
Other versions
DE60309888T2 (de
Inventor
Etienne Pays
Luc Vanhamme
Francoise Paturiaux-Hanocq
Philippe Poelvoorde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Original Assignee
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB filed Critical Universite Libre de Bruxelles ULB
Publication of DE60309888D1 publication Critical patent/DE60309888D1/de
Application granted granted Critical
Publication of DE60309888T2 publication Critical patent/DE60309888T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/101—Bovine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DE60309888T 2002-08-02 2003-08-04 Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen Expired - Lifetime DE60309888T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
BE200200465 2002-08-02
BE200200465 2002-08-02
BE200200649 2002-11-14
BE200200649 2002-11-14
PCT/BE2003/000131 WO2004012757A2 (en) 2002-08-02 2003-08-04 Apolipoprotein l-i for the treatment or diagnosis of prypanosomaldiseases

Publications (2)

Publication Number Publication Date
DE60309888D1 true DE60309888D1 (de) 2007-01-04
DE60309888T2 DE60309888T2 (de) 2007-06-21

Family

ID=31496437

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60309888T Expired - Lifetime DE60309888T2 (de) 2002-08-02 2003-08-04 Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen

Country Status (9)

Country Link
US (1) US7585511B2 (de)
EP (1) EP1534320B1 (de)
AT (1) ATE345808T1 (de)
AU (1) AU2003254426A1 (de)
DE (1) DE60309888T2 (de)
DK (1) DK1534320T3 (de)
ES (1) ES2278201T3 (de)
PT (1) PT1534320E (de)
WO (1) WO2004012757A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039645A1 (en) * 2005-10-06 2007-04-12 Vib Vzw African trypanosomiasis therapy with a nanobody-conjugated human trypanolytic factor
ES2402789T3 (es) 2006-11-20 2013-05-08 President And Fellows Of Harvard College Métodos, composicones y kits para tratar dolor y prurito
WO2009124941A2 (en) * 2008-04-07 2009-10-15 Aarhus Universitet Trypanocidal compounds targeted to trypanosomes interior
WO2010129267A2 (en) 2009-04-27 2010-11-11 University Of Georgia Research Foundation, Inc. Anti-trypanosomal peptides and uses thereof
EP2451944A4 (de) 2009-07-10 2012-11-28 Harvard College Permanent geladene natrium- und calciumkanalblocker als entzündungshemmende mittel
US20110030078A1 (en) * 2009-07-31 2011-02-03 New York University Trypanosome resistant non-human transgenic animal
AP2012006112A0 (en) * 2009-08-18 2012-02-29 Univ Bruxelles C-terminal mutant of apolipoprotein L-I and its therapeutical or prophylactic use.
CA2768640A1 (en) * 2009-08-18 2011-02-24 Universite Libre De Bruxelles Apolipoprotein l-i variants and their use
US9023355B2 (en) * 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
WO2011133474A2 (en) * 2010-04-18 2011-10-27 Beth Israel Deaconess Medical Center Methods of predicting predisposition to or risk of kidney disease
USRE49076E1 (en) 2010-04-18 2022-05-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
WO2012057934A1 (en) * 2010-10-26 2012-05-03 The Rockefeller University Immunogenic agents
WO2012095508A1 (en) * 2011-01-13 2012-07-19 Universite Libre De Bruxelles Apol3 for use in the treatment of trypanosoma infectious diseases
EP2489365A1 (de) * 2011-02-17 2012-08-22 Université Libre de Bruxelles Wildtyp-Apolipoprotein l-i zur Prävention von Nierenerkrankungen
CN103458918A (zh) * 2011-03-25 2013-12-18 纽约哥伦比亚大学理事会 聚乙二醇化人类hdl粒子和其制造方法
US20150291683A1 (en) * 2012-11-16 2015-10-15 Merck Sharp & Dohme Corp. Modified apol1 polypeptides
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US20150307591A1 (en) * 2012-12-21 2015-10-29 Merck Sharp & Dohme Corp. On-column refolding and purifying of lipoproteins
US9751936B2 (en) 2013-03-08 2017-09-05 Regeneron Pharmaceuticals, Inc. Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
EP3552488A1 (de) 2014-11-10 2019-10-16 F. Hoffmann-La Roche AG Tiermodell für nephropathie und mittel zur behandlung davon
MX2018001447A (es) 2015-08-03 2019-02-21 Harvard College Bloqueadores de canal de ion cargado y metodos para su uso.
BR112021017809A2 (pt) 2019-03-11 2021-11-23 Nocion Therapeutics Inc Bloqueadores de canais iônicos substituídos por éster e métodos para uso
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527690A (ja) 2019-03-11 2022-06-03 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2023500890A (ja) 2019-11-06 2023-01-11 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
AU2020380118A1 (en) 2019-11-06 2022-05-19 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2023517604A (ja) 2020-03-11 2023-04-26 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
ATE302267T1 (de) * 1998-01-08 2005-09-15 Aventis Pharma Inc Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert

Also Published As

Publication number Publication date
ATE345808T1 (de) 2006-12-15
US20060263348A1 (en) 2006-11-23
AU2003254426A8 (en) 2004-02-23
EP1534320B1 (de) 2006-11-22
DK1534320T3 (da) 2007-04-02
WO2004012757A2 (en) 2004-02-12
ES2278201T3 (es) 2007-08-01
US7585511B2 (en) 2009-09-08
EP1534320A2 (de) 2005-06-01
DE60309888T2 (de) 2007-06-21
WO2004012757A3 (en) 2004-04-15
AU2003254426A1 (en) 2004-02-23
PT1534320E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
DE60309888D1 (de) Apolipoprotein l-i zur behandlung von trypanosomen-erkrankungen
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE602005013788D1 (de) ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE502006001740D1 (de) Zusammensetzung zur Vorbeugung und Behandlung von Erkältungskrankheiten
ATE315400T1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE354361T1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE323505T1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition